

Shionogi Highlights Japan's Role in Advancing Global Health in Dialogue with Bill Gates
- Discussing the Fight Against Infectious Diseases and the Future of Sustainable Healthcare Models
under the Theme "Japan's Role in Advancing Global Health Progress" -

OSAKA, Japan, Sep. 25, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi") announced that its Chief Executive Officer, Isao Teshirogi, Ph.D. participated in a dialogue with Bill Gates, Chair of the Gates Foundation, at the international event *Innovation in Action: Harnessing Japan's R&D Potential for Global Health*, hosted by the Gates Foundation in Tokyo on August 19, 2025. Under the theme "Japan's Role in Advancing Global Health Progress," the two leaders discussed the fight against infectious diseases and the future of sustainable healthcare models.



From left – Ms. Keiko Tashiro (Moderator, Deputy President, Daiwa Securities Group Inc.), Bill Gates (Chair, Gates Foundation), Dr. Isao Teshirogi (CEO, Shionogi), Photo credit: Gates Archive/Ben Beechey

The event brought together over 300 participants from government, academia, research institutions, and industry to explore how Japan's scientific capabilities and public-private partnerships can contribute to solving global health challenges, including those faced by low- and middle-income countries (LMICs).

During the dialogue, Dr. Teshirogi stated:

“The fight against infectious diseases is almost the belief or philosophy of the company. These are global challenges that transcend borders. By leveraging Japan’s technology and expertise, we aim to build sustainable healthcare models through global collaboration. This includes the use of AI and technology transfer to LMICs. It is essential that we work together to shape the future of healthcare.”

In response, Gates commented:

“Japan’s culture of mutual respect and its advanced technology make it a potential model for global healthcare. AI has the power to revolutionize both drug discovery and healthcare delivery, improving efficiency by up to 40%. By combining Japan’s experience with AI, we can expand contributions to underserved regions. I encourage everyone to actively embrace AI and consider how their area of expertise can help address global challenges.



Photo credit: Gates Archive/Ben Beechey

Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” and “Improve access to healthcare” as our key focus. Shionogi is actively strengthening its collaborative efforts, both domestically and internationally, to realize total care for infectious diseases. This includes research and development of novel therapeutics, as well as initiatives across the entire care continuum—raising awareness, epidemiologic monitoring, prevention, diagnosis, management of disease progression, and treatment. As a leading company in infectious diseases, we will continue to actively address various infectious diseases, including antimicrobial resistance, and COVID-19, which constitute major public health issues.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related

forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>

Reference:

1, Press Release from the Gates Foundation: [ビル・ゲイツ、日本のグローバルヘルス分野における重要な役割を強調 | ゲイツ財団のプレスリリース](#)